Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
- Status
- RECRUITING
- Phase
- PHASE2
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- Status
- RECRUITING
- Phase
- PHASE1
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
PR3-AAV Resilient Remission or PRRR
- Status
- TERMINATED
- Phase
- PHASE2
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Genotype-guided Treatment in DLBCL
- Status
- RECRUITING
- Phase
- PHASE3
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
- Status
- UNKNOWN
- Phase
- PHASE3
Population Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseases
- Status
- UNKNOWN
- Phase
- N/A
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
- Status
- SUSPENDED
- Phase
- PHASE1
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2